- Home
- BMEA vs ESP Comparison
BMEA vs ESP Comparison
Compare BMEA & ESP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- ESP
- Stock Information
- Founded
- BMEA 2017
- ESP 1928
- Country
- BMEA United States
- ESP United States
- Employees
- BMEA N/A
- ESP N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- ESP Industrial Machinery/Components
- Sector
- BMEA Health Care
- ESP Technology
- Exchange
- BMEA Nasdaq
- ESP Nasdaq
- Market Cap
- BMEA 125.0M
- ESP 148.8M
- IPO Year
- BMEA 2021
- ESP N/A
- Fundamental
- Price
- BMEA $1.66
- ESP $37.32
- Analyst Decision
- BMEA Strong Buy
- ESP
- Analyst Count
- BMEA 8
- ESP 0
- Target Price
- BMEA $10.63
- ESP N/A
- AVG Volume (30 Days)
- BMEA 3.1M
- ESP 44.4K
- Earning Date
- BMEA 10-28-2025
- ESP 11-12-2025
- Dividend Yield
- BMEA N/A
- ESP 2.72%
- EPS Growth
- BMEA N/A
- ESP 31.88
- EPS
- BMEA N/A
- ESP 3.02
- Revenue
- BMEA N/A
- ESP $43,950,872.00
- Revenue This Year
- BMEA N/A
- ESP N/A
- Revenue Next Year
- BMEA N/A
- ESP N/A
- P/E Ratio
- BMEA N/A
- ESP $12.18
- Revenue Growth
- BMEA N/A
- ESP 13.46
- 52 Week Low
- BMEA $1.29
- ESP $24.85
- 52 Week High
- BMEA $12.85
- ESP $55.00
- Technical
- Relative Strength Index (RSI)
- BMEA 41.51
- ESP 31.74
- Support Level
- BMEA $1.66
- ESP $37.85
- Resistance Level
- BMEA $2.99
- ESP $39.94
- Average True Range (ATR)
- BMEA 0.19
- ESP 1.69
- MACD
- BMEA -0.06
- ESP -0.09
- Stochastic Oscillator
- BMEA 3.96
- ESP 18.10
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.